Neopharma invests BD90m for diabetes management
Manama : Neopharma announced investing BD90 million (US$290m) towards diabetes management in the Gulf Cooperation Council (GCC) and other global markets.
This includes an investment of BD10m (US$27m) in a state-of-the-art Japanese factory, BD27m (US$72m) in the acquisition of patents and licenses and an additional investment in clinical studies amounting to BD53m (US$140m).
The factory in Japan will manufacture supplements for patients in the pre-diabetic stage and also Type II diabetes patients. Clinical studies for NatuALA is being conducted across USA, Japan, UK and Bahrain.
Neopharma Japan has acquired a 65 per cent stake in the Japanese pharmaceutical company, Cosmo ALA (now known as Neo ALA), to manufacture this dietary supplement.
“Medical technology now enables more accurate diagnosis for better monitoring, prevention and management of illnesses, many of them deemed life-threatening or incapacitating earlier. Innovations in this pre-diabetes arena will help people live healthier, longer and more active lives,” commented Dr. B.R. Shetty, Chairman & Managing Director, Neopharma.
Neopharma’s factory in Japan has started the production to meet the needs of the Type 2 diabetes patients in the GCC region and across the globe. Neopharma will be distributing the product worldwide.
Neopharma announced its plans in the presence of Assistant Undersecretary of Public Health Policy and Licensing – Dr. Amin Al Amiri, Japanese Ambassador to the UAE, Kanji Fujiki, Prof. Tohru Tanaka, Prof. Naohide Yamashita among other senior officials. The launch event focused on the history and development of 5-ALA and its application in Type 2 Diabetes Mellitus.
Related Posts